Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial
Authors
Keywords
-
Journal
PHARMACOECONOMICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-09
DOI
10.1007/s40273-021-01068-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A systematic review of economic evaluations of treatment regimens in multiple myeloma
- (2020) Mir Mahmood Asrar et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Efficacy and Safety of Once‐Weekly versus Twice‐Weekly Bortezomib in Patients with Hematologic Malignancies: A Meta‐analysis with Trial Sequential Analysis
- (2019) Bin Hu et al. PHARMACOTHERAPY
- Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia
- (2019) Zimu Gong et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Patient‐Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Ajai Chari et al. ONCOLOGIST
- Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba
- (2019) Maria-Victoria Mateos et al. BLOOD
- Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)
- (2018) C Pelligra et al. VALUE IN HEALTH
- Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
- (2018) Xavier Leleu et al. Clinical Lymphoma Myeloma & Leukemia
- Economic burden of multiple myeloma among patients in successive lines of therapy in the United States
- (2017) Joanna P. MacEwan et al. LEUKEMIA & LYMPHOMA
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Trends in overall survival and costs of multiple myeloma, 2000–2014
- (2016) R Fonseca et al. LEUKEMIA
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece
- (2013) Vassilis Fragoulakis et al. Cancer Management and Research
- Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
- (2012) J. Jaime Caro et al. VALUE IN HEALTH
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
- (2010) S. Bringhen et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now